NICE gives Aubagio the nod

Share this article:

The UK's price watchdog NICE has approved Sanofi's oral MS medication Aubagio for adults with relapsing-remitting multiple sclerosis, which means the National Health Service will begin funding the drug within the next three months.

Wednesday's thumbs-up is a re-tread. NICE told Sanofi in September that Sanofi had to provide cost-effectiveness data that would indicate the drug deserves a space on the formulary compared to what's already on the market. The drug costs around $22,500 per patient per year in the UK.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.